BPTH — Bio Path Holdings Share News
0.000.00%
Last trade - 00:00Bio-Path: Jumps on completing safety check of cancer treatment trial
Brief: Bio-Path Holdings Announces Successful Completion Of Safety Cohort Of Triple Combination Of Prexigebersen, Decitabine And Venetoclax In Stage 2 Of Phase 2 Clinical Trial In Acute Myeloid Leukemia
Brief: Bio-Path Holdings Reports Full Year 2020 Financial Results
U.S. STOCKS ON THE MOVE-CVS Health, AutoNation, Cortexyme, Socket Mobile
U.S. STOCKS ON THE MOVE-Kala, Carnival Corp, CrowdStrike, Diffusion
Bio-Path slides on equity offering
Brief: Bio-Path Announces Pricing Of $13 Million Public Offering Of Common Stock
Brief: Bio-Path Holdings Announces Proposed Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE-Twitter, Enphase Energy, Match Group, Mesa Air, Under Armour
U.S. STOCKS ON THE MOVE-Twitter, Match Group, Treehouse Foods, Enphase Energy
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:27 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:46 AM
Bio Path: Jumps on third U.S. patent for drug manufacturing tech
Brief: Bio-Path Receives Third U.S. Patent Grant Related To Manufacture Of Platform Technology
Brief: Bio-Path Holdings Announces First Patient Dosed In Phase 1 Clinical Trial Of Bp1002
Brief: Bio-Path Holdings Reports Third Quarter 2020 Financial Results
Bio Path: Up on U.S. patent for potential cancer therapy
Brief: Bio-Path Receives Notice Of Allowance For Strategic Patent For Prexigebersen In Combination With Front Line Cytidine Analogues Or Bcr-Abl Tyrosine Kinase Inhibitors In A Variety Of Cancers
NASDAQ RESUMED AT 10:48 AM